RESULTS FOR : 'Oncology'
Showing 1 to 11 of 11 results |    
Keyword Search
Show#
Show#
Results Category/Section
Something old, something new... a marriage of technologies for immuno-oncology in vivo studies

Discovering and validating novel therapeutic targets to add to the immuno-oncology arsenal will require refined preclinical models that meet the needs for suitability, scalability and clinical relevancy throughout the various phases of target discovery and drug validation.

Immuno-Oncology's Biomarker Dilemma How to add value in an uncertain development landscape

Given their ability to promote long-term survival in a percentage of cancer patients, PD-1/PD-L1 checkpoint inhibitors have fast become foundational cancer therapies. But knowing which patients may respond to these drugs is challenging, in large part because good predictive biomarkers have yet to be identified and validated.

Kinases and drug discovery: protein kinases as a validated drug target.

The role of protein and lipid kinases in cellular physiology and normal and abnormal growth has been well appreciated and has been the focus of intensive research in both academic arenas and pharmaceutical industries. The payoff for the pharmaceutical industries has been substantial.

CRISPR Cas9: transforming gene editing in drug discovery labs

It is evident from a recent market survey on gene editing in drug discovery that CRISPR/Cas9 is now recognised as the superlative method when attempting a gene knockout or when introducing defined mutations, insertions or modifications to the genome.

Fusion Therapy - a new approach to combining treatments

Increasingly, oncology agents are being used in combination. However, with complications such as drug resistance and unfavourable side-effect profiles, researchers have been looking for new ways to enhance treatment effect and tolerability. New fusion technology molecules appear to offer a beneficial synergy, but will this withstand clinical investigation and what is its future potential?

The role of immunodeficient animal models in advancing immuno-oncology research

From inbred wild-type to more advanced genetically-engineered strains, mouse models enable researchers to gain important insights into the complex biological underpinnings of human cancer.

Synthetic lethality and anti cancer drug discovery

Classically-activated oncogene targets have been a mainstay of cancer drug discovery for the past 15 years, but the druggable targets in this category have been largely mined out.

Valuation in portfolio management.

Throughout the course of my career, I have been involved in a wide range of portfolio decisions and continue to be involved in them today. Over the years, it has been observed that despite cultural differences, pharma teams face similar problems.

The use of syngeneic models for the discovery of targets for combination therapy and predictive biomarkers of immunotherapy efficacy.

Optimal treatment for any disease is one that can cure or prevent spreading with minimal impact on the patient’s quality of life. In the case of cancer, therapeutic agents were initially designed to kill rapidly dividing cells.

CAR-T : Looking beyond the hype.

While CAR-Ts have already demonstrated convincing efficacy in a specific setting, the jury is still out on whether they are a ‘game-changer’ for oncology as a whole and can justify current valuations and investor interest.

Immunotherapeutics: the coming of age of cancer immunotherapy as a treatment paradigm.

As the oncology drug development landscape has evolved, so too have the processes, methods and equipment used in the fight against cancer. Traditional treatments such as chemotherapy and radiation therapy are still very popular and remain effective methods of fighting the disease as a whole.